JP2991642B2 - エスクロシドを含む調製物および薬剤および美容分野におけるそれらの使用 - Google Patents
エスクロシドを含む調製物および薬剤および美容分野におけるそれらの使用Info
- Publication number
- JP2991642B2 JP2991642B2 JP17465895A JP17465895A JP2991642B2 JP 2991642 B2 JP2991642 B2 JP 2991642B2 JP 17465895 A JP17465895 A JP 17465895A JP 17465895 A JP17465895 A JP 17465895A JP 2991642 B2 JP2991642 B2 JP 2991642B2
- Authority
- JP
- Japan
- Prior art keywords
- escroside
- flavone
- cosmetic
- treatment
- cellulitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000003814 drug Substances 0.000 title claims 4
- 229940079593 drug Drugs 0.000 title claims 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 title 1
- 230000003796 beauty Effects 0.000 title 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 12
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 11
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 10
- 229930003944 flavone Natural products 0.000 claims description 10
- 235000011949 flavones Nutrition 0.000 claims description 10
- 206010007882 Cellulitis Diseases 0.000 claims description 9
- 235000017276 Salvia Nutrition 0.000 claims description 9
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 9
- 150000002212 flavone derivatives Chemical class 0.000 claims description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 6
- 229960000278 theophylline Drugs 0.000 claims description 6
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 5
- 244000194101 Ginkgo biloba Species 0.000 claims description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 5
- 229960001948 caffeine Drugs 0.000 claims description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 5
- 239000000539 dimer Substances 0.000 claims description 5
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 5
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000002366 lipolytic effect Effects 0.000 claims description 4
- 229960001476 pentoxifylline Drugs 0.000 claims description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 3
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical group C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 3
- 229930004069 diterpene Natural products 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 150000004141 diterpene derivatives Chemical class 0.000 claims description 2
- 229940122869 Adenylate cyclase stimulant Drugs 0.000 claims 2
- 235000011201 Ginkgo Nutrition 0.000 claims 1
- 240000007164 Salvia officinalis Species 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001072909 Salvia Species 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000002414 leg Anatomy 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 102000030621 adenylate cyclase Human genes 0.000 description 5
- 108060000200 adenylate cyclase Proteins 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 201000002282 venous insufficiency Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 201000002816 chronic venous insufficiency Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
- 229940105039 coconut extract Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 241000157280 Aesculus hippocastanum Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HITDPRAEYNISJU-UHFFFAOYSA-N amenthoflavone Natural products Oc1ccc(cc1)C2=COc3c(C2=O)c(O)cc(O)c3c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HITDPRAEYNISJU-UHFFFAOYSA-N 0.000 description 1
- YUSWMAULDXZHPY-UHFFFAOYSA-N amentoflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 YUSWMAULDXZHPY-UHFFFAOYSA-N 0.000 description 1
- HVSKSWBOHPRSBD-UHFFFAOYSA-N amentoflavone Natural products Oc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HVSKSWBOHPRSBD-UHFFFAOYSA-N 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 229940031661 dimethicone 350 Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- NQJGJBLOXXIGHL-UHFFFAOYSA-N podocarpusflavone A Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O NQJGJBLOXXIGHL-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Description
独でまたはフォルスコリンまたはサルビア・ミルチオリ
ザ(Salvia miltiorrhiza)ジテルペンなどのアデニル
酸シクラーゼ刺激剤および/またはアピゲニン骨格構造
を有する2量体フラボンなどのホスホジエステラーゼイ
ンヒビターと組み合わせて含む末梢血管微小循環障害に
関係する末梢血管疾患の治療における局所的使用のため
の調製物に関し、さらに、本発明は、蜂巣炎または過剰
脂肪沈着と関連した反美容症候(unesthetisms)の治療
におけるエスクロシドの単独使用または上記のアデニル
酸シクラーゼ刺激剤および/または上記のホスホジエス
テラーゼインヒビターとの配合使用に関する。後者に関
して、上記化合物にはカフェイン、テオフィリン、ペン
トキシフィリンを加えることができる。
のエスクロシドの単独使用またはフォルスコリンまたは
サルビア・ミルチオリザジテルペンなどのアデニル酸シ
クラーゼ刺激剤および/またはアピゲニン骨格構造を有
する2量体フラボンなどのホスホジエステラーゼインヒ
ビターとの配合使用に関する。
の果皮およびAesculus hippocastanum(トチノキ)の樹
皮から抽出されるクマリン配糖体であって、そのような
化合物は浸透性障害および毛細血管脆弱に関連した病理
学的状態の治療において長年使用されており、これは今
も静脈鬱血性血管疾患、痔疾の治療における局所的また
は全身的適用のため、および眼科学における鬱血除去薬
として使用されている。今、驚いたことに、エスクロシ
ドの単独適用または上記の化合物との配合適用を局所的
に行った場合に適用領域における動脈血流の増加(動脈
の伸縮性細胞および前毛細血管小動脈への活性がその脈
拍動を増加する)および灌流毛細血管数の増加の双方が
もたらされ、それによって表面部および深部の循環が改
善されることが見出された。この現象は、赤外線光パル
ス血量計、レーザードップラー流量計およびコンピュー
タ化されたビデオ毛細管顕微鏡などの非侵襲的方法によ
って測定された。最初の二つの方法によって動脈および
前毛細血管小動脈の血管運動性が明示され、後者によっ
て毛細血管床および脈管形成域における変化を評価する
ことができる。基礎データを記録した後、プラセボ調製
物または活性組成物または活性主成分を含む調製物を治
療すべき生体領域に適用する。通常、二つの対称の生体
部分を用いて、試験をランダム化する。治療処理後直ち
に、処理領域を、ハロゲン光プローブを供えた50〜4
00倍の倍率のビデオ毛細管顕微鏡(Scopeman-Moritex
Video Imaging System, Alfa Strumenti、ミラノ)を
用いて、毛細管密度(単位表面当たりの血液灌流された
毛細血管数)を測定して、毛細血管の空間配置およびそ
れらの形態を評価する。この機器は生物顕微鏡画像を連
続的に記録するためのビデオカメラを備えており、処理
段階中の変化を定量することができる。エスクロシドの
単独または最も重要な化合物例としてGinkgo biloba2
量体フラボンまたはアメントフラボンなどの上記の化合
物との併用による処理の20分後、基礎的およびプラセ
ボ処理の対照と比較して200〜300%までの毛細血
管密度の増加が起きた。上記のようにして評価された
0.5〜3%の範囲の濃度のエスクロシドの作用は、1
〜3時間持続する。上記したようにビデオ毛細管顕微鏡
によって、皮膚微細脈管形成を評価し、灌流された毛細
血管数および空間配置およびその層形成を明らかにする
ことが可能である。
たはアデニル酸シクラーゼ刺激活性または抗ホスホジエ
ステラーゼ活性を有する化合物および適宜また、カフェ
イン、テオフィリン、ペントキシフィリンなどの他の脂
肪分解剤と併用して含む調製物を、蜂巣炎などの慢性静
脈欠陥による疾患を有する領域または強制食餌に続く反
美容症候などの過剰脂肪蓄積に適用した場合、エスクロ
シドおよび他の化合物による脂肪分解作用による領域微
小循環の改善によって症状の顕著な軽減が驚いたことに
認められ、これが本発明の一部をなす。適用は病理症状
または反美容症候の軽重によるが、2、3日間から数カ
月、通常は3カ月間の範囲で行われる。
または抗ホスホジエステラーゼ剤またはアデニル酸シク
ラーゼ刺激剤との配合で、慢性静脈機能不全、レイノー
病および肢端チアノーゼにおいておよび風邪誘導性血管
痙攣、とくに手指および足指の微小循環における血管痙
攣において使用することができる。該活性成分を用いて
処理した領域の高められた血流はまた、老化初期の真
皮、とくに顔および首の皮膚、蜂巣炎様の皮膚、皮下組
織層疾患および妊娠線に好ましく作用する。さらに、高
められた血液供給はまた、頭皮などの滑らかではない皮
膚に好ましく作用し、一次および二次脱毛症の治療に有
用である。
る使用は、先進工業国人口に大きな割合で影響を及ぼし
ている皮膚の老化および蜂巣炎に関する。
(段階I)の患者20人を二つのグループに分けて、
1.5%エスクロシドを含む調製物またはプラセボを用
いて大腿内転筋から足首までに1日に2回適用して、3
カ月間治療した。
ける増加のビデオ毛細管顕微鏡測定による急性試験によ
って応答能を評価した。処理後20分の測定によると、
プラセボで治療したグループの毛細血管密度は8.6±
2.2%であり、エスクロシド治療を受けたグループで
は18.6±3.1%であった(ステュデントのtテス
トによる計算でp<0.01)。
の範囲のスコアによって評価され、次表のように報告さ
れる。
の前後の脚静脈機能不全の患者における症状の評価 患者番号 前 1 2 3 4 5 6 7 8 9 10 後 1 2 3 4 5 6 7 8 9 10 脚のだるさ 00 32 21 31 20 31 21 32 00 31 浮腫 00 21 31 20 10 32 10 21 10 31 感覚性錯覚 10 20 00 10 31 20 00 21 10 10 昼間痙攣 00 42 20 31 00 20 31 20 00 00 夜間痙攣 00 31 10 31 00 10 20 11 00 00 静脈拡張 11 11 22 11 22 33 11 33 11 00 静脈瘤 00 00 00 00 11 11 00 00 00 00 神経性脚 00 41 30 42 31 42 20 30 10 31 冷足 32 41 42 41 42 31 42 42 42 31
の前後の脚静脈機能不全の症状の程度の平均±標準誤差
(対データのためのステュデントのtテストによる統計
評価) 症状 前 後 p< 脚のだるさ 2.1 ± 0.38 0.9 ± 0.23 p< 0.01 浮腫 1.8 ± 0.33 0.6 ± 0.22 p< 0.01 感覚性錯覚 1.5 ± 0.34 0.3 ± 0.15 p< 0.01 昼間痙攣 1.6 ± 0.48 0.4 ± 0.22 p< 0.01 夜間痙攣 1.1 ± 0.38 0.3 ± 0.15 p< 0.05 静脈拡張 1.5 ± 0.31 1.5 ± 0.31 有意ではない。 静脈瘤 0.2 ± 0.13 0.2 ± 0.13 有意ではない。 神経性脚 2.7 ± 0.42 0.7 ± 0.26 p< 0.01 冷足 3.7 ± 0.15 1.6 ± 0.16 p< 0.01
て、20人の対象グループを大腿内転筋領域から足首ま
でを1.5%のエスクロシド、0.3%のサルビア・ミ
ルチオリザ抽出物(この抽出物は15%のタンシノンA
2を含む)、0.4%Ginkgo biloba2量体フラボン(イ
ンデナ(INDENA)特許EP0360556に従って調製)
および0.2%テオフィリンを含む調製物で3カ月間治
療した。これらの対象において、第1図のデータ報告に
示されるように観察されたパラメターは大きく変化し
た。
腿内転筋領域の線維硬化性皮下組織層疾患20人の対象
グループを、1.5%のエスクロシド、0.3%のサル
ビア・ミルチオリザ抽出物および1%のペントキシフィ
リンを含む調製物で2カ月間治療した。主なコントロー
ルパラメターは、過剰脂肪蓄積の減少だったので、大腿
内転筋領域の直径を測定したが、これは2.6±0.2
cmという驚異的な減少を示した。
するために組成物構成および組成物の割合または組成物
の性質を変えて他の多くの試験が行われた。本発明によ
る調製物は、上記の活性成分の他に、従来のキャリア、
添加物、保存剤などの以下の非限定的実施例に示すよう
な薬剤技術において公知の物質を含む。
抽出物およびGinkgo biloba2量体フラボンを含むゲル 100グラムのゲルは以下の組成を有する。
フェインを含むアルコール性液体ゲル 100gのゲルは以下の組成を有する。
抽出物およびカフェイン様アルカロイド中で滴定された
コラナッツ抽出物を含むクリーム100gのクリームは
以下の組成を有する。
ローション剤100mlのローション剤は以下の組成を
有する。
100gのゲル化エマルジョンは以下の組成を有する。
Claims (6)
- 【請求項1】 活性成分としてのエスクロシドを、アデ
ニル酸シクラーゼ刺激剤、ホスホジエステラーゼインヒ
ビターおよび脂肪分解剤から選択された少なくとも1種
と組み合わせて含むことを特徴とする、抹消微小循環障
害に関連する抹消血管疾患、蜂巣炎または過剰脂肪蓄積
に関連した反美容症候の治療用の局所使用のための薬剤
および/または美容用調製物。 - 【請求項2】 アデニル酸シクラーゼ刺激剤として、フ
ォルスコリンまたはサルビア・ミルチオリザジテルペ
ン、あるいはこれらの混合物を含む請求項1に記載の薬
剤および/または美容用調製物。 - 【請求項3】 ホスホジエステラーゼインヒビターとし
てアピゲニン骨格を有する2量体フラボンを含む請求項
1または2に記載の薬剤および/または美容用調製物。 - 【請求項4】 フラボンをギンゴー・ビロバ(Ginkgo b
iloba)2量体フラボンおよびアメントフラボンから選
択した請求項3に記載の薬剤および/または美容用調製
物。 - 【請求項5】 脂肪分解剤としてカフェイン、テオフィ
リンまたはペントキシフィリン、あるいはこれらの混合
物を含む請求項1〜4のいずれかに記載の薬剤および/
または美容用調製物。 - 【請求項6】 エスクロシドを活性成分として含有する
ことを特徴とする、抹消微小循環障害に関連する抹消血
管疾患、蜂巣炎または過剰脂肪蓄積に関連した反美容症
候の治療用の局所使用のための薬剤および/または美容
用調製物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT94A001446 | 1994-07-12 | ||
ITMI941446A IT1270602B (it) | 1994-07-12 | 1994-07-12 | Formulazioni a base di esculoside e loro uso in campo farmaceutico e cosmetico |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08169896A JPH08169896A (ja) | 1996-07-02 |
JP2991642B2 true JP2991642B2 (ja) | 1999-12-20 |
Family
ID=11369257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP17465895A Expired - Fee Related JP2991642B2 (ja) | 1994-07-12 | 1995-07-11 | エスクロシドを含む調製物および薬剤および美容分野におけるそれらの使用 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5679358A (ja) |
EP (1) | EP0692250B1 (ja) |
JP (1) | JP2991642B2 (ja) |
KR (1) | KR100255527B1 (ja) |
AT (1) | ATE218339T1 (ja) |
AU (1) | AU686381B2 (ja) |
CA (1) | CA2153604C (ja) |
DE (1) | DE69526882T2 (ja) |
DK (1) | DK0692250T3 (ja) |
ES (1) | ES2177593T3 (ja) |
HK (1) | HK1011617A1 (ja) |
IT (1) | IT1270602B (ja) |
PT (1) | PT692250E (ja) |
SG (1) | SG44320A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1245230A3 (en) * | 1995-06-23 | 2003-11-26 | Advanced Life Sciences Inc. | Amentoflavone as an antiviral agent |
BR9602919A (pt) * | 1996-06-27 | 1999-01-12 | Cosmeticos Natural Ind Com | Composições cosméticas para o cuidado da pele |
JP3768626B2 (ja) * | 1996-12-02 | 2006-04-19 | 株式会社カネボウ化粧品 | 脂肪分解促進剤および痩身用皮膚化粧料 |
FR2774905B1 (fr) * | 1998-02-17 | 2000-06-09 | Codif International Sa | Utilisation d'une composition cosmetique comportant au moins une substance qui comprend un groupement pyrone |
JP2002506806A (ja) * | 1998-03-16 | 2002-03-05 | ザ、プロクター、エンド、ギャンブル、カンパニー | 皮膚の外観を調節する組成物 |
AU767582B2 (en) * | 1998-11-26 | 2003-11-20 | Andrew John Pollitt | The use of a botanical substance given in high dilution to treat or prevent pathologic infiltration of the phospholipid cytoplasmic outer membrane of the human cell |
DE10009423A1 (de) * | 2000-02-28 | 2001-09-06 | Henkel Kgaa | Kosmetische und pharmazeutische Zubereitungen |
WO2001074327A1 (en) * | 2000-04-04 | 2001-10-11 | Color Access, Inc. | Composition for improving skin lipid barrier function |
KR20030005204A (ko) * | 2000-12-25 | 2003-01-17 | 가부시키가이샤 시세이도 | 교감신경 활성화 향료 조성물 |
EP1234572B1 (de) * | 2001-02-26 | 2013-10-30 | Mibelle AG Cosmetics | Isoflavon-Aglykone enhaltende Hautbehandlungsmittel |
FR2836630B1 (fr) * | 2002-03-01 | 2004-07-09 | Lvmh Rech | Utilisation cosmetique de la phytosphingosine comme agent amincissant et compositions cosmetiques contenant de la phytosphingosine |
AU2003288109A1 (en) * | 2002-11-22 | 2004-06-18 | L'oreal | Cosmetic composition, containing coumarin derivatives and lipophilic amino acid derivatives |
FR2847466B1 (fr) * | 2002-11-22 | 2004-12-24 | Oreal | Composition notamment cosmetique contenant des derives de coumarines et des derives lipophiles d'acide amine |
ITMI20031427A1 (it) * | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi, loro uso in campo farmaceutico e cosmetico e formulazioni che li contengono |
ITMI20031428A1 (it) | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi e loro uso per il trattamento di disfunzioni sessuali |
DE10352602A1 (de) * | 2003-11-11 | 2005-06-02 | Rovi Gmbh & Co. Kosmetische Rohstoffe Kg | Kosmetisches oder therapeutisches Kombinationspräparat |
ITMI20040214A1 (it) * | 2004-02-10 | 2004-05-10 | Aboca S P A | Composizioni cosmetiche contenenti associazioni estratti di bulpeurum species e salvia milthiorriza per la riduzione ed il contenimento degli inestetismi della cellulite |
JP2008523127A (ja) | 2004-12-14 | 2008-07-03 | メナリーニ リチェルケ ソシエタ ペル アチオニ | セルライトの治療のための医薬品組成物 |
WO2012087779A2 (en) * | 2010-12-21 | 2012-06-28 | The Procter & Gamble Company | Hair care compositions and methods to improve hair appearance |
ITMI20110373A1 (it) * | 2011-03-10 | 2012-09-11 | Erbolario S R L L | "composizioni cosmetiche per il trattamento degli inestetismi cutanei della cellulite" |
ITMI20111671A1 (it) * | 2011-09-16 | 2013-03-17 | Indena Spa | Composizioni per il trattamento di ulcere periferiche di varia origine |
CN109620840A (zh) * | 2018-12-27 | 2019-04-16 | 江苏隆力奇生物科技股份有限公司 | 一种抗皮肤光老化的药物组合物及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1175430A (en) | 1914-10-20 | 1916-03-14 | Albert Fry | Road-grader. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT275028B (de) * | 1968-05-31 | 1969-10-10 | Nattermann & Cie Arzneimittel | Verfahren zur Gewinnung eines aescinreichen Wirkstoffkonzentrates aus Roßkastaniensamen |
DE1939008A1 (de) * | 1969-07-31 | 1971-02-11 | Zander Dr Helmut | Arzneimittelkombination zur Behandlung von Mangeldurchblutungen des Gehirns |
FR2499405A1 (fr) * | 1981-02-10 | 1982-08-13 | Biotherm | Composition cosmetique amincissante et anti-cellulitique a base d'un extrait de plante contenant des saponines, un extrait d'arnica montana l. et d'un extrait de noix de cola et son procede d'application |
FR2583640A1 (fr) * | 1985-06-24 | 1986-12-26 | Berdal Pascal | Compositions pharmaceutiques a visee vasculotrope et antisclereuse |
GB8518289D0 (en) * | 1985-07-19 | 1985-08-29 | Inverni Della Beffa Spa | Obtaining proanthocyanidine a2 |
HU202743B (en) * | 1988-06-24 | 1991-04-29 | Richter Gedeon Vegyeszet | Active ingredient composition comprising medicinal herb extracts, cosmetics comprising such active ingredient and process for producing medicinal and veterinary compositions |
IT1232318B (it) * | 1989-09-07 | 1992-01-28 | Crinos Industria Farmaco | Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo. |
IT1233753B (it) * | 1989-09-21 | 1992-04-14 | Indena Spa | Composizioni farmaceutiche ad attivita' sulla microcircolazione cutanea. |
IT1239281B (it) * | 1989-10-27 | 1993-10-19 | Indena Spa | Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica |
FR2669537B1 (fr) * | 1990-11-28 | 1993-02-19 | Oreal | Composition amincissante a base d'alpha-2-bloqueurs. |
GB9104286D0 (en) * | 1991-02-28 | 1991-04-17 | Phytopharm Ltd | Pharmaceutical compositions for the treatment of skin disorders |
-
1994
- 1994-07-12 IT ITMI941446A patent/IT1270602B/it active IP Right Grant
-
1995
- 1995-07-05 EP EP95110463A patent/EP0692250B1/en not_active Expired - Lifetime
- 1995-07-05 DE DE69526882T patent/DE69526882T2/de not_active Expired - Lifetime
- 1995-07-05 PT PT95110463T patent/PT692250E/pt unknown
- 1995-07-05 ES ES95110463T patent/ES2177593T3/es not_active Expired - Lifetime
- 1995-07-05 DK DK95110463T patent/DK0692250T3/da active
- 1995-07-05 AT AT95110463T patent/ATE218339T1/de not_active IP Right Cessation
- 1995-07-06 US US08/498,868 patent/US5679358A/en not_active Expired - Lifetime
- 1995-07-11 JP JP17465895A patent/JP2991642B2/ja not_active Expired - Fee Related
- 1995-07-11 CA CA002153604A patent/CA2153604C/en not_active Expired - Fee Related
- 1995-07-11 AU AU24919/95A patent/AU686381B2/en not_active Ceased
- 1995-07-11 SG SG1995000837A patent/SG44320A1/en unknown
- 1995-07-11 KR KR1019950020385A patent/KR100255527B1/ko not_active IP Right Cessation
-
1998
- 1998-12-07 HK HK98112885A patent/HK1011617A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1175430A (en) | 1914-10-20 | 1916-03-14 | Albert Fry | Road-grader. |
Also Published As
Publication number | Publication date |
---|---|
HK1011617A1 (en) | 1999-07-16 |
JPH08169896A (ja) | 1996-07-02 |
DE69526882D1 (de) | 2002-07-11 |
CA2153604C (en) | 2008-12-02 |
EP0692250B1 (en) | 2002-06-05 |
DE69526882T2 (de) | 2003-01-02 |
CA2153604A1 (en) | 1996-01-13 |
EP0692250A2 (en) | 1996-01-17 |
ES2177593T3 (es) | 2002-12-16 |
ATE218339T1 (de) | 2002-06-15 |
ITMI941446A1 (it) | 1996-01-12 |
DK0692250T3 (da) | 2002-09-30 |
AU686381B2 (en) | 1998-02-05 |
IT1270602B (it) | 1997-05-07 |
US5679358A (en) | 1997-10-21 |
SG44320A1 (en) | 1997-12-19 |
AU2491995A (en) | 1996-01-25 |
PT692250E (pt) | 2002-09-30 |
KR100255527B1 (ko) | 2000-05-01 |
EP0692250A3 (en) | 1996-10-23 |
ITMI941446A0 (it) | 1994-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2991642B2 (ja) | エスクロシドを含む調製物および薬剤および美容分野におけるそれらの使用 | |
JP4611460B2 (ja) | クマリンを含む調製物および薬剤および美容分野におけるそれらの使用 | |
Hexsel et al. | Cosmeceuticals for cellulite | |
RU2113216C1 (ru) | Косметический состав (варианты) | |
US5720963A (en) | Barrier disruption treatments for structurally deteriorated skin | |
US8017138B2 (en) | Composition and method for treating skin | |
EP2821056A1 (en) | Cosmetic composition, formulation gel-cream and its use | |
JPH08333260A (ja) | 皮膚外用剤 | |
KR100315583B1 (ko) | 흉터를아물게하는활성을가진국소약물 | |
KR0132730B1 (ko) | 피부 미소순환에 작용하는 약학 조성물 | |
US20050182076A1 (en) | Transdermal penetration system and treatment for cellulite | |
EA019237B1 (ru) | Соединения, пригодные для лечения целлюлита | |
US20140302185A1 (en) | Composition for the treatment of skin lesions | |
Hexsel et al. | Topical management of cellulite | |
JP2013536169A (ja) | ヘスペレチンの新規使用 | |
US20070243271A1 (en) | Use of polyphenols to treat skin conditions | |
KR20100005538A (ko) | 피부 손상 치료용 조성물 | |
EA020417B1 (ru) | Композиции для лечения розацеи | |
JP2004514689A (ja) | 表面血流刺激性スキンクリーム | |
KR100257228B1 (ko) | 에스쿨로시드를 포함하는 미용 조성물 | |
CN112057386A (zh) | 一种清爽保湿美白修复的防晒乳及其制备方法 | |
EP4085894A1 (en) | Composition for eye contour to prevent, reduce and/or eliminate skin imperfections | |
Caputo | The spectrum of treatments for photodamage | |
HU221141B1 (en) | Composition for cellulite treatments and process for its preparation | |
RO129526A2 (ro) | Cremă destinată eliminării vitiligo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071015 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081015 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091015 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101015 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101015 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111015 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |